The Blood–brain barrier (BBB) is a highly selective semipermeable frontier of endothelial cells that prevents solutes in the circulating blood from non-selectively crossing into the extracellular fluid of the central nervous system where neurons reside.
BBB has been a great barrier to brain drug delivery. This is a healthy brain is a diffusion barrier essential for protecting normal brain function by impeding most compounds across the blood to the brain and only small molecules can cross the BBB.
A blood-brain barrier maintains homeostasis by obstructing toxic molecules from the circulation, but drugs are blocked at the same time. When the dose is increased to enhance the drug concentration in the central nervous system, then there will be side-effects on peripheral organs. In recent years, genetic therapeutic agents and small molecules have been used in various strategies to penetrate the BBB while minimizing the damage to systemic organs.
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan